Skip to Content
MilliporeSigma
All Photos(1)

Key Documents

View All Documentation

C-059

Supelco

Clozapine solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H19ClN4
CAS Number:
5786-21-0
Molecular Weight:
326.82
EC Number:
200-659-6
MDL number:
MFCD00153785
UNSPSC Code:
41116107
NACRES:
NA.24

grade

certified reference material

Quality Level

300

form

liquid

feature

SNAP-N-SPIKE®, SNAP-N-SHOOT®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

Storage temp.

−20°C

SMILES string

CN1CCN(CC1)C2=Nc3cc(Cl)ccc3Nc4ccccc24

InChI

1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3

Inchi Key

QZUDBNBUXVUHMW-UHFFFAOYSA-N

Gene Information

human ... DRD2(1813) , HTR2A(3356)

General description

A Certified Snap-N-Spike® Solution for use in clinical toxicology, forensic analysis, or urine drug testing applications by LC/MS or GC/MS. Clozapine, sold as Clozaril® and FazaClo® in the US, is an atypical antipsychotic drug used for treatment of schizophrenia.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Clozaril is a registered trademark of Sandoz, Inc.
FazaClo is a registered trademark of Jazz Pharmaceuticals International III Limited
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

Storage Class

3 - Flammable liquids

wgk_germany

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chun-Hsin Chen et al.
The Journal of clinical psychiatry, 74(5), e424-e430 (2013-06-14)
Many studies have shown that metformin can decrease body weight and improve metabolic abnormalities in patients with schizophrenia. Whether or not the beneficial effects can be sustained after discontinuation of metformin needs to be evaluated. We conducted a 24-week randomized
Benjamin W J Spencer et al.
Pharmacogenomics, 14(15), 1907-1914 (2013-11-19)
Clozapine is a uniquely efficacious antipsychotic drug in treatment-resistant schizophrenia. Its use is restricted due to adverse effects including a rare but dangerous reduction in neutrophils (agranulocytosis) and the mandatory hematological monitoring this entails in many countries. We review the
Rasmus Røge et al.
Schizophrenia research, 140(1-3), 204-213 (2012-07-27)
Clozapine remains the drug of choice for treatment resistant schizophrenia, but is associated with potentially life threatening side effects, including agranulocytosis and myocarditis. Immunological mechanisms may be involved in the development of these side effects or in the unique antipsychotic
Saeko Ikai et al.
The Annals of pharmacotherapy, 47(7-8), e31-e31 (2013-06-13)
To report on a patient who was successfully rechallenged with clozapine after perforation of the large intestine and pulmonary embolism post operatively, and provide a literature review on clozapine rechallenge. A 46-year-old Japanese man with treatment-resistant schizophrenia developed constipation and
Adam P Hill et al.
Molecular pharmacology, 85(5), 769-776 (2014-03-04)
The Kv11.1 potassium channel is the molecular target for the majority of drugs implicated in acquired long QT syndrome, the most common cause of drug-induced sudden cardiac death, and a common reason for drug restriction or withdrawal from the market.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service